Finance

Lists
Outlook: 13.6% bullish·59.1% bearish
Go to analysis
NPCE:NASDAQ
Neuropace Inc
$8.14
-0.97%
(-0.080) 1D
$8.14
0.00% (0.00)
After hours
Closed: Nov 19, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NPCE...
Open
$8.37
High
$8.38
Low
$8.08
Mkt. cap
280.44M
Avg. vol.
398.04K
Volume
211.07K
52-wk high
$19.60
52-wk low
$5.47
EPS
-$0.56
Beta
1.98
Shares outstanding
34.45M
No. of employees
216
Open
$8.37
High
$8.38
Low
$8.08
Mkt. cap
280.44M
Avg. vol.
398.04K
Volume
211.07K
52-wk high
$19.60
52-wk low
$5.47
EPS
-$0.56
Beta
1.98
Shares outstanding
34.45M
No. of employees
216
News stories
From web sources and news partners
About Neuropace Inc
CEO-
Employees216
Founded1997
Headquarters-
SectorHealth Care
IndustryMedical device
Analyst ratings
Based on 8 analysts giving stock ratings to NPCE in the past 3 months
Buy
Buy
5
Hold
3
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for NPCE in the last 3 months.
Highest
Current $8.14
$14.00 (+71.99%)
Average
$11.13 (+36.73%)
Lowest
$8.00 (-1.72%)
Analyst
Recommendation
Action
Price target
Projected
Date
Mike Kratky
Leerink Partners
Hold
Reiterated
$8.00
-1.7%
11/19/2026
Anthony Petrone
Mizuho Securities
Buy
Maintained
$12.00
+47.4%
11/16/2026
Yi Chen
H.C. Wainwright
Buy
Reiterated
$12.00
+47.4%
11/16/2026
Frank Takkinen
Lake Street
Buy
Maintained
$13.00
+59.7%
11/13/2026
Larry Biegelsen
Wells Fargo
Hold
Downgraded
$9.00
+10.6%
11/13/2026
Brett Fishbin
KeyBanc
Buy
Maintained
$14.00
+72%
11/13/2026
Lilia-Celine (Lily) Lozada
J.P. Morgan
Hold
Downgraded
$9.00
+10.6%
11/13/2026
Sarah James
Cantor Fitzgerald
Buy
Reiterated
$12.00
+47.4%
11/13/2026
Unknown Analyst
J.P. Morgan
Buy
Maintained
$20.00
+145.7%
08/12/2026
Rohin K Patel
J.P. Morgan
Buy
Maintained
$20.00
+145.7%
05/12/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
26.59M
22.07M
22.83M
23.10M
Cost of goods sold
6.01M
4.02M
3.92M
3.63M
Cost of revenue
6.01M
4.02M
3.92M
3.63M
Research and development expenses
7.03M
7.19M
6.90M
6.17M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
15.32M
16.43M
17.15M
15.38M
Operating expense
22.34M
23.62M
24.05M
21.55M
Total operating expenses
28.36M
27.64M
27.97M
25.18M
Operating income
-1.77M
-5.57M
-5.14M
-2.08M
Other non operating income
-41.00K
-165.00K
-41.00K
36.00K
EBT including unusual items
-2.73M
-6.69M
-6.20M
-3.30M
EBT excluding unusual items
-2.77M
-6.69M
-6.20M
-3.10M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-2.73M
-6.69M
-6.20M
-3.30M
Net profit margin
-10.26%
-30.31%
-27.16%
-14.27%
Earnings per share
-0.08
-0.20
-0.18
-0.10
Interest and investment income
638.00K
565.00K
523.00K
511.00K
Interest expense
-1.60M
-1.52M
-1.54M
-1.56M
Net interest expenses
-962.00K
-956.00K
-1.02M
-1.05M
Depreciation and amortization charges
-
-
-
-
EBITDA
-1.69M
-5.51M
-5.08M
-2.00M
Gain or loss from assets sale
12.00K
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps